HERON THERAPEUTICS, INC. /DE/ HRTX

Latest FY: 2025 Healthcare Biotechnology
Market Price $0.33
Market Cap $62.46M
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑7.4% YoY
$154.90M
3-Yr CAGR: 12.9%
Net Income ↓-48.7% YoY
-$20.20M
Net Margin: -13.0%
Free Cash Flow ↓-15.2% YoY
-$27.91M
FCF Yield: -44.68%
EPS (Diluted) ↓-33.3% YoY
$-0.12
Basic: $-0.12
Return on Equity Efficiency
-140.9%
ROA: -7.9%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (HRTX)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $1.3M $1.2M $-173.1M 0.00% $-134.1M $-137.2M
FY 2017 $30.8M +2,305.6% $26.2M $-197.5M -14.1% 0.00% $-170.3M $-172.9M -26.0%
FY 2018 $77.5M +151.8% $50.0M $-178.8M +9.4% 0.00% $-191.8M $-201.0M -16.3%
FY 2019 $146.0M +88.4% $84.3M $-204.7M -14.5% 0.00% $-124.6M $-131.7M +34.5%
FY 2020 $88.6M -39.3% $52.4M $-227.3M -11.0% 0.00% $-184.8M $-191.6M -45.5%
FY 2021 $86.3M -2.6% $40.3M $-220.7M +2.9% $-2.24 0.00% $-203.4M $-206.4M -7.7%
FY 2022 $107.7M +24.7% $52.8M $-182.0M +17.5% $-1.67 +25.4% 0.00% $-146.9M $-148.7M +27.9%
FY 2023 $127.0M +18.0% $61.9M $-110.6M +39.3% $-0.80 +52.1% 0.00% $-58.8M $-60.3M +59.4%
FY 2024 $144.3M +13.6% $105.6M $-13.6M +87.7% $-0.09 +88.8% 0.00% $-22.5M $-24.2M +59.8%
FY 2025 $154.9M +7.4% $113.6M $-20.2M -48.7% $-0.12 -33.3% 0.00% $-27.6M $-27.9M -15.2%
$

Valuation

Market Price $0.33
Market Cap $62.46M
Enterprise Value $33.82M
P/E Ratio N/A
P/B Ratio 4.40
FCF Yield -44.68%
Dividend Yield N/A
Shares Outstanding 189,279,400
%

Profitability & Margins

Gross Margin 73.31%
Operating Margin -1.64%
Net Margin -13.04%
Return on Equity (ROE) -140.90%
Return on Assets (ROA) -7.89%
Asset Turnover 0.61x
Revenue 3-Yr CAGR 12.89%
🛡️

Financial Health & Liquidity

Current Ratio 2.48
Cash Ratio 0.30
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents $28.65M
Total Debt N/A
Book Value / Share $0.08
💧

Cash Flow Efficiency

Operating Cash Flow -$27.59M
Capital Expenditures (CapEx) $317.00K
Free Cash Flow -$27.91M
OCF / Revenue -17.81%
FCF / Revenue -18.02%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-0.12
EPS (Basic) $-0.12
Dividends / Share N/A
Book Value / Share $0.08
EPS YoY Growth -33.33%
🏛️

Balance Sheet (FY 2025)

Total Assets $255.88M
Total Liabilities $241.54M
Stockholders' Equity $14.33M
Current Assets $238.07M
Current Liabilities $96.10M